Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3 Recruiting
186 enrolled
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Phase 3 Recruiting
320 enrolled
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
698 enrolled
MK-2400-001
Phase 3 Recruiting
1,440 enrolled
TroFuse-033
Phase 3 Recruiting
1,123 enrolled
KLK2-PASenger
Phase 3 Recruiting
800 enrolled
RASolve 301
Phase 3 Recruiting
420 enrolled
DE-01
Phase 3 Recruiting
600 enrolled
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Phase 3 Recruiting
572 enrolled
ARTEMIA
Phase 3 Recruiting
363 enrolled
MEVPRO-1
Phase 3 Recruiting
600 enrolled
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3 Recruiting
1,100 enrolled
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Phase 3 Recruiting
1,260 enrolled
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Phase 3 Recruiting
540 enrolled
OPTION-DDR
Phase 3 Recruiting
236 enrolled
TROPION-Lung17
Phase 3 Recruiting
400 enrolled
Fern-EC-01
Phase 3 Recruiting
480 enrolled
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Phase 3 Recruiting
740 enrolled
rechARge
Phase 3 Recruiting
960 enrolled
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Phase 3 Recruiting
387 enrolled
Magic-C002
Phase 3 Recruiting
446 enrolled
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Phase 3 Recruiting
300 enrolled
TRIPLE-SWITCH
Phase 3 Recruiting
830 enrolled
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Phase 3 Recruiting
510 enrolled
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Phase 3 Recruiting
300 enrolled
COMET
Phase 3 Recruiting
133 enrolled
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Phase 3 Recruiting
2,400 enrolled
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Phase 3 Recruiting
125 enrolled
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
Phase 3 Recruiting
460 enrolled
ECLIPSE
Phase 3 Recruiting
412 enrolled
STAMPEDE2
Phase 3 Recruiting
3,360 enrolled
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Phase 3 Recruiting
544 enrolled
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Phase 3 Recruiting
400 enrolled
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma
Phase 3 Recruiting
508 enrolled
LEDANG
Phase 3 Recruiting
123 enrolled
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Phase 3 Recruiting
880 enrolled
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer
Phase 3 Recruiting
680 enrolled
Neo-Healer
Phase 3 Recruiting
520 enrolled
ProBio
Phase 3 Recruiting
750 enrolled
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Phase 3 Recruiting
657 enrolled
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3 Recruiting
400 enrolled
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
Phase 3 Recruiting
500 enrolled
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
Phase 3 Recruiting
630 enrolled
PREVENT
Phase 3 Recruiting
200 enrolled
NEOSAMBA
Phase 3 Recruiting
444 enrolled
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
Phase 3 Recruiting
522 enrolled
NEOPCOSCC
Phase 3 Recruiting
309 enrolled
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Phase 3 Recruiting
490 enrolled
Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH
Phase 3 Recruiting
286 enrolled
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Phase 3 Recruiting
372 enrolled